GENEGENETIC TECHNOLOGIES LTD

Nasdaq genetype.com


$ 0.89 $ -0.01 (-1.44 %)    

Wednesday, 21-Aug-2024 15:59:59 EDT
QQQ $ 471.89 $ -0.69 (-0.15 %)
DIA $ 413.95 $ 2.57 (0.62 %)
SPY $ 559.30 $ 0.05 (0.01 %)
TLT $ 97.51 $ -0.32 (-0.33 %)
GLD $ 232.94 $ 1.20 (0.52 %)
$ 0.887
$ 0.78 x 100
-- x --
-- - --
$ 0.69 - $ 23.25
10,540
na
682,497
$ 1.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 genetic-technologies-transitions-to-a-capital-light-operating-model-with-lower-cost-operations-continued-focus-on-the-cos-core-business-of-easydna-and-genetype-working-capital-funded-by-short-term-800000-secured-loan-active-channel-partners-in-the-usa-with-genetype-sales-growth-easydna-sales-of-7m-and-growing

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based te...

 genetic-technologies-appoints-mark-ziirsen-as-chief-financial-officer

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tes...

 genetype-announces-the-introduction-of-suite-of-genetic-risk-assessment-tests-to-canada-and-new-zealand

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tes...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION